Points of View

To drive patient-centricity, the life sciences industry needs to stop acting like a B2B industry

The life sciences industry must balance intense margin pressure with significant reputational risk. The industry has to transform while simultaneously managing pricing pressures, low R&D returns, and a changing product mix (rise of biologics, personalized medicine, and med-tech). Will COVID-19 become the burning platform that pushes the life sciences industry to undertake a fundamental transformation? Is there a silver lining to this sad pandemic that has engulfed the globe?

 

Sign in or register an account to access HFS' Content

Sign In

Create an account

Enter a phone number
Select the newsletter(s) to which you wish to subscribe.